Merck - 52 Year Stock Price History | MRK

Historical daily share price chart and data for Merck since 1970 adjusted for splits. The latest closing stock price for Merck as of November 25, 2022 is 107.50.
  • The all-time high Merck stock closing price was 107.50 on November 25, 2022.
  • The Merck 52-week high stock price is 107.50, which is 0% above the current share price.
  • The Merck 52-week low stock price is 71.50, which is 33.5% below the current share price.
  • The average Merck stock price for the last 52 weeks is 86.42.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Merck Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2022 86.6422 74.9819 107.5000 71.7044 107.5000 43.80%
2021 74.0300 76.2138 87.4972 67.9391 74.7576 -2.92%
2020 74.7881 83.9860 83.9860 61.0712 77.0046 -7.21%
2019 73.9104 67.1514 83.7122 64.7795 82.9913 22.26%
2018 56.0943 48.4440 69.9795 46.2726 67.8799 40.00%
2017 52.6831 50.2827 56.5248 46.2211 48.4871 -1.47%
2016 47.2527 42.4992 53.8937 39.3490 49.2126 15.05%
2015 44.9652 44.8112 49.3872 38.8685 42.7745 -3.87%
2014 44.0801 37.6234 48.1211 37.6234 44.4978 16.95%
2013 34.5748 30.2998 38.0491 29.9407 38.0491 26.80%
2012 29.5951 26.9470 34.8113 26.2505 30.0066 13.13%
2011 23.3993 24.2151 26.6656 20.4797 26.5249 9.54%
2010 23.6433 23.8441 26.4340 20.7116 24.2151 2.86%
2009 18.5867 18.9426 24.4819 13.0364 23.5413 26.73%
2008 22.0382 33.5533 35.4132 14.1926 18.5760 -45.34%
2007 29.1907 24.9815 35.5418 24.3686 33.9861 37.36%
2006 21.3123 17.8571 26.0031 17.8571 24.7431 42.66%
2005 16.2585 16.2150 18.3366 13.9150 17.3446 4.04%
2004 21.2848 23.5039 24.5415 13.3042 16.6715 -27.76%
2003 25.2436 26.7884 29.4705 20.1113 23.0793 -11.35%
2002 24.4997 26.7957 29.0240 17.7195 26.0342 -1.26%
2001 31.4725 40.7848 40.7848 25.6344 26.3653 -35.79%
2000 32.0650 29.1509 41.5522 23.3624 41.0610 41.78%
1999 31.3006 31.7891 36.7877 26.0582 28.9613 -7.48%
1998 27.1141 22.4832 33.6778 21.5011 31.3011 41.32%
1997 19.5465 16.3865 22.4205 16.3865 22.1488 35.61%
1996 13.7988 12.9031 17.1962 11.5041 16.3332 23.92%
1995 9.8160 7.5136 13.4313 7.1456 13.1803 76.57%
1994 6.3990 6.6658 7.7094 5.4136 7.4647 14.82%
1993 6.5295 8.0541 8.0541 5.3466 6.5013 -18.35%
1992 8.8143 9.9819 10.1313 7.5082 7.9623 -20.29%
1991 7.1257 5.2662 9.9891 4.8396 9.9891 88.88%
1990 4.5880 4.5110 5.2886 3.8757 5.2886 18.95%
1989 3.9935 3.2063 4.5633 3.2063 4.4461 37.47%
1988 3.0243 2.9933 3.3103 2.6497 3.2343 12.05%
1987 3.0614 2.2946 3.9609 2.2946 2.8864 27.95%
1986 1.7411 1.2566 2.3583 1.2327 2.2558 80.83%
1985 0.9998 0.8480 1.2475 0.8230 1.2475 45.75%
1984 0.8069 0.8230 0.8832 0.7262 0.8559 4.00%
1983 0.8281 0.7649 0.9492 0.7466 0.8230 6.81%
1982 0.7000 0.7785 0.7990 0.5850 0.7705 -0.16%
1981 0.7915 0.7831 0.9322 0.6966 0.7717 0.00%
1980 0.6624 0.6442 0.7717 0.5349 0.7717 17.30%
1979 0.6148 0.6181 0.6726 0.5702 0.6579 6.85%
1978 0.5244 0.4882 0.6295 0.4382 0.6157 21.82%
1977 0.5113 0.6101 0.6101 0.4587 0.5054 -18.52%
1976 0.6512 0.6340 0.7319 0.5736 0.6203 -1.63%
1975 0.6781 0.6123 0.7785 0.5349 0.6306 4.33%
1974 0.6544 0.7319 0.7796 0.4462 0.6044 -17.80%
1973 0.8134 0.8240 0.9151 0.7080 0.7353 -9.39%
1972 0.6955 0.5702 0.8149 0.5702 0.8115 43.76%
1971 0.4826 0.4325 0.5953 0.4325 0.5645 25.25%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $272.555B $48.704B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $463.391B 17.83
Eli Lilly (LLY) United States $347.053B 43.79
AbbVie (ABBV) United States $282.285B 11.70
Pfizer (PFE) United States $276.231B 7.55
Novo Nordisk (NVO) Denmark $268.818B 35.25
Novartis AG (NVS) Switzerland $194.067B 14.62